BVS
Q4 2026 EPS Estimate
$0.17
Nov 3, 2026 · Reports before open
Revenue Estimate
$150M
FY2026E EPS$0.78
FY2027E EPS$0.92

Analyst Sentiment

Wall St. Consensus
Buy
7 analysts·Limited coverage
68
Score
5 Buy (71%)2 Hold (29%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
571%
Hold
229%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$18.00
+28.4%
Consensus
$18.00
+28.4%
Bull
$19.00
+35.5%
12-Month Target Range7 analysts
$18.00$18.00$19.00
Current $14.02Consensus
Current Price
$14.02
Upside to Consensus
$3.98

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+6.75%
EPS+18.44%
FY2028
Rev+6.47%
EPS+15.38%
FY2029
Rev+7.50%
EPS+2.64%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$605M$646M$687M$739M$795M
Low$603M$638M$684M$734M$791M
High$607M$653M$693M$745M$802M
EBITDA Avg$8M$9M$9M$10M$11M
Low$8M$8M$9M$10M$10M
High$8M$9M$9M$10M$11M
EBIT Avg$-49M$-52M$-56M$-60M$-64M
Low$-49M$-53M$-56M$-60M$-65M
High$-49M$-52M$-55M$-59M$-64M
Net Income Avg$54M$63M$92M$75M$85M
Low$53M$63M$54M$75M$84M
High$54M$64M$96M$76M$86M
EPS Avg$0.78$0.92$1.06$1.09$1.23
Low$0.77$0.91$0.79$1.08$1.22
High$0.79$0.93$1.40$1.10$1.24
Analysts (Rev / EPS)4 / 44 / 44 / 42 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$150M$170M$140M$163M$158M$181M$149M$172M
Low$148M$169M$139M$162M$157M$180M$148M$171M
High$151M$171M$141M$164M$159M$182M$150M$173M
EBITDA Avg$2M$2M$2M$2M$2M$2M$2M$2M
Low$2M$2M$2M$2M$2M$2M$2M$2M
High$2M$2M$2M$2M$2M$2M$2M$2M
EBIT Avg$-12M$-14M$-11M$-13M$-13M$-15M$-12M$-14M
Low$-12M$-14M$-11M$-13M$-13M$-15M$-12M$-14M
High$-12M$-14M$-11M$-13M$-13M$-15M$-12M$-14M
Net Income Avg$11M$18M$11M$17M$16M$22M$12M$21M
Low$11M$17M$11M$17M$15M$22M$12M$21M
High$11M$18M$11M$17M$16M$22M$12M$21M
EPS Avg$0.16$0.25$0.15$0.24$0.22$0.31$0.17$0.30
Low$0.16$0.24$0.15$0.24$0.22$0.31$0.17$0.30
High$0.16$0.25$0.15$0.24$0.22$0.32$0.17$0.30
Analysts (Rev / EPS)3 / 33 / 31 / 11 / 11 / 11 / 11 / 21 / 2

Earnings Surprises

Recent Analyst Actions

Aug 17, 2026Canaccord Genuity
Bioventus price target raised to $19 from $15 at Canaccord
Target:$19.00
+33.2%from $14.26
Aug 6, 2026Craig-Hallum
Bioventus price target raised to $18 from $16 at Craig-Hallum
Target:$18.00
+29.8%from $13.87
Aug 6, 2026Barrington
Bioventus price target raised to $18 from $14 at Barrington
Target:$18.00
+18.0%from $15.26
Jun 16, 2026Canaccord Genuity
Canaccord Reiterates Buy Rating on Bioventus Inc (BVS)
Target:$15.00
+74.4%from $8.60
Feb 9, 2026Barrington
Bioventus initiated with an Outperform at Barrington
Target:$13.00
+52.8%from $8.51
May 7, 2025Craig-Hallum
Bioventus price target lowered to $15 from $17 at Craig-Hallum
Target:$15.00
+141.9%from $6.20
Oct 1, 2024Canaccord Genuity
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
Target:$12.00
+1.8%from $11.79
Aug 7, 2024Craig-Hallum
Bioventus price target raised to $12 from $9 at Craig-Hallum
Target:$12.00
+45.5%from $8.25
May 7, 2024Canaccord Genuity
Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity
Target:$8.00
+56.3%from $5.12
Mar 13, 2024Craig-Hallum
Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum
Target:$9.00
+70.1%from $5.29
Nov 30, 2022Goldman Sachs
Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5
Target:$2.50
+30.9%from $1.91
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.